In a phase 3 trial, 67% of children treated with omalizumab tolerated 600 mg of peanut protein, a dramatic increase over just 7% with placebo, highlighting omalizumab’s potential in managing pediatric food allergies.
Eighty FCCs had properties that warrant further investigation for potential health concerns, such as carcinogenic, mutagenic, and reproductive toxicity.
New analysis reveals U.S. nonprofit hospitals received $37.4 billion in tax benefits in 2021, with more than half attributed to state and local taxes. The benefits varied significantly by state and were concentrated among a small number of hospitals.
From overflowing cribs to empty pediatric wings, new data reveals a 133.3% difference in children's hospital bed occupancy rates between the most and least crowded states.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A new proteomic risk score based on 32 blood proteins may predict an increased likelihood of developing chronic obstructive pulmonary disease and respiratory-related mortality, offering potential for early disease detection without the need for long-term spirometry monitoring.